Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @LineageCell
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LineageCell
-
Lineage is developing a novel
#celltherapy to treat dry age-related macular degeneration (#AMD), the leading cause of irreversible vision loss in the US. OpRegen is currently in Phase I/IIa and has the potential to help many patients. https://investor.lineagecell.com/news-releases/news-release-details/lineage-provides-update-patient-enrollment-phase-iiia-clinical …pic.twitter.com/hxZ6YjG9v3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
What is OPC1? OPC1 is an oligodendrocyte progenitor
#celltherapy for the treatment of acute spinal cord injuries (#SCI), partially funded through our partnership with@CIRM. Learn more about this therapy: http://lineagecell.com/products-pipeline/opc1/ …pic.twitter.com/ZKLQ0S2GLE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Learn about the
#DryAMD competitive landscape in this week's Lineage#IRMinute where$LCTX CEO Brian Culley discusses how OpRegen is positioned in contrast to our competitorspic.twitter.com/amyBLWIRLBHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The overall safety profile of OPC1 has remained excellent with robust motor recovery in upper extremities maintained through Year 2 SCiStar Study patient follow-ups available Learn more about our
#spinalcordinjury cell therapy development: https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-provides-update-scistar-clinical-study …pic.twitter.com/X1WYgTRbip
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. Learn more about the innovative
#celltherapies in our pipeline: https://lineagecell.com/products-pipeline/ …pic.twitter.com/vHUn8zLoIb
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Top industry execs including
$LCTX CFO Brandi Roberts came together to discuss "where#healthcare is headed" with@ZTracer of@businessinsider#JPM20pic.twitter.com/UztRfKiTpp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$LCTX CEO Brian Culley chatted with Proactive’s Christine Corrado in San Francisco#celltherapy#JPM20https://youtu.be/1E-xjV_nfEIHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
On the OPC1 Phase 1/2a trial, principal investigator Dr. Donald Leslie commented: “If OPC1 could deliver even modest improvements in motor or sensory function, it would result in significant improvements in quality of life for people with SCI.”pic.twitter.com/qP79WnE7E7
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Great lunch today with
$LCTX CEO Brian Culley and other industry execs discussing the cutting edge in#celltherapy with@AndrewE_Dunn of@BioPharmaDive#JPM20pic.twitter.com/qDNsvjuDaA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lineage Cell Therapeutics proslijedio/la je Tweet
At
@LineageCell, they are developing#celltherapies to fight macular degeneration, spinal cord injuries and cancer.@CEO_Culley talks to@GreggStebben of@Forbes_Books at#JPM20.pic.twitter.com/fKOW5m3dwP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
"Lineage's vision restoration cell therapy is a one-two punch. One technology with two product candidates and different methods of action. Stopping degenerative disease for early stage and restoring visual function for late state
#AMD." -Francois Binette$LCTX at#biotechshowcaseHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
"Our goal with the Vision Restoration Program is to develop transformational cell therapies that will have a great impact on the relatively unaddressed blinding retinal diseases to restore visual function." -Francois Binette, Global Head of R&D at
$LCTXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are at
#biotechshowcase today with Global Head of R&D at$LCTX, Francois Binette, presenting an update on our Vision Restoration Program.pic.twitter.com/szdaVedupg
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$LCTX CEO Brian shares#celltherapy#techtrends for patients with#dryAMD, spinal cord injuries, and cancer! Data from multiple#celltherapy programs are expected to read out this year.#JPM2020https://twitter.com/russopartners/status/1216713282721021952 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A look into our future shows us pursuing opportunities to obtain development support for our
#celltherapy programs through external partnerships.#plansfor2020#JPM2020pic.twitter.com/Oktpgeao6Y
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Be in the know! Watch this week’s Lineage
#IRMinute with CEO Brian Culley discussing the clinical development of#VAC2 and the research partnership with@CR_UK.$LCTX#celltherapypic.twitter.com/G0WikjlgYXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We look forward to collecting additional data on OpRegen and completing enrollment of our Phase I/IIa study for
#dryAMD in Q1 2020.#lookingforwardto2020#JPM2020 Learn more about our trial here: https://clinicaltrials.gov/ct2/show/NCT02286089 …pic.twitter.com/iJrdEM1hV2
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lineage continues to provide updates to the SCiStar Study, which so far has an excellent safety profile and robust motor recovery maintained.
#lookingforwardto2020#JPM2020 Learn more about the study results here: https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-provides-update-scistar-clinical-study …pic.twitter.com/lhv12JRUT6
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lineage is looking forward to
#JPM2020! Our executive team will be reviewing the$LCTX clinical programs and 2020 plans.#investors#partnering#celltherapy#lookingforwardto2020pic.twitter.com/o0x0wymE09
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.